

## SWIXX BIOPHARMA EXPANDS PARTNERSHIP WITH ELI LILLY TO BRAZIL

**Baar, Switzerland, March 4<sup>th</sup>, 2026** – Swixx BioPharma AG of Baar, Switzerland, is delighted to announce today that Swixx BioPharma company has concluded a Distribution and Promotion agreement with Eli Lilly Export S.A. (“Lilly”). Under the agreement, Biopas, a Swixx BioPharma company, is appointed to commercialize and distribute Lilly’s medicine Omvoh™ (mirikizumab-mrkz) in Brazil.

As per it’s FDA label, Omvoh™ is an interleukin-23 antagonist indicated for the treatment of moderately to severely active ulcerative colitis in adults and moderately to severely active Crohn’s disease in adults<sup>1</sup>.

 **Pascal Forget, Regional General Manager Latam**, commented: “We are delighted to extend Swixx Group’s existing partnership with Eli Lilly to Latam’s most important market, Brazil. This partnership demonstrates that our growing capabilities in Brazil and Latin America in general, as well as our expertise to launch innovative products, are recognized and trusted by top multinational companies. We are confident that this partnership positions Biopas on a trajectory of continued expansion in the region.”

 **Fabio Turcato Ivankovich, General Manager Brazil**, continued: “This partnership represents a big milestone for our Brazilian organization, significantly accelerating our growth. With a sense of urgency and great enthusiasm, we will work hard with our physicians, scientific community and payors to bring Omvoh™ to Brazilian patients as soon as possible. We thank Eli Lilly for their confidence in Biopas and consider it a privilege to work with such innovative therapies.”

### About Swixx Group

Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With full-fledged subsidiaries in 47 countries, more than 2,000 employees and sales which exceeded 1.4 billion Euros in 2025, the Group is one of the fastest-growing independent commercialization platforms for biopharma globally. Swixx has gathered outstanding rare disease, oncology-hematology, GI, specialty, vaccines and CNS therapy area talent under one roof. For more information about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com).



**Swixx Group investor and partner inquiries, LATAM:**

Jose Flament, Head of Business Development Latam and ROW  
[BD.LATAM@swixxbiopharma.com](mailto:BD.LATAM@swixxbiopharma.com)

**Swixx Group media inquiries:**

Vedrana Sokac Brataljenovic, Public Affairs Director  
[vedrana.sokac@swixxbiopharma.com](mailto:vedrana.sokac@swixxbiopharma.com), Tel: +385 1 425 6086

References:

1. US Food and Drug Administration, Prescribing information Omvoh. Available at :  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761279s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761279s003lbl.pdf). Last accesses February 2026.

